Similarly, we identify mutations in both tumor-suppressor genes, e.g., ABL1, JAK2, MAP2K1, and KIT [38], from poor responders in CML, suggesting that these are two of the key mechanisms by which tumor cells evolve to acquire drug resistance. Here, MAP2K1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.